SEC Form 4 · Rule 10b5-1 trading plans
VERACYTE, INC. (VCYT)
- 11Trades filed under a plan
- 5Plan adoption dates stated
- 8Quarterly results prints on file
- 0Trades in the days before a print
In the 2025 filing year, VERACYTE, INC. filed 7 Form 4 statements whose footnotes name a Rule 10b5-1 trading plan, by 5 reporting owners, covering 11 transactions filed under those plans and 81,727 shares. None carries the SEC's own AFF10B5ONE adoption flag; each of the 7 names a plan in a footnote. 8 results prints are on file in the same window, which is what makes the interval below measurable.
Trades filed under a plan in VERACYTE, INC. 11
- EASTHAM KARIN — 2025-01-02 · S · 5,309 shares
- EASTHAM KARIN — 2025-01-02 · S · 4,691 shares
- Chambers Rebecca — 2025-02-03 · S · 527 shares
- McGuire Annie — 2025-03-04 · S · 1,142 shares
- Stapley Marc — 2025-03-04 · S · 28,189 shares
- Stapley Marc — 2025-03-04 · S · 23,414 shares
- Stapley Marc — 2025-03-04 · S · 1,094 shares
- Leite John — 2025-03-07 · S · 2,400 shares
- Leite John — 2025-03-07 · S · 5,011 shares
- Stapley Marc — 2025-09-04 · S · 7,667 shares
- McGuire Annie — 2025-09-19 · S · 2,283 shares
Plan adoption dates stated in VERACYTE, INC. 5
- 2024-08-13 — stated in 1 filing
- 2024-08-20 — stated in 1 filing
- 2024-09-04 — stated in 2 filings
- 2024-09-13 — stated in 2 filings
- 2024-12-06 — stated in 1 filing
Quarterly results prints on file in VERACYTE, INC. 8
- 2025-02-24
- 2025-05-07
- 2025-08-06
- 2025-11-04
- 2026-01-12
- 2026-02-25
- 2026-05-05
- 2026-07-30
Trades in the days before a print in VERACYTE, INC. 0
- 21 days before the 2025-02-24 print — 2025-02-03 · S · Chambers Rebecca · 527 shares
- 46 days before the 2025-11-04 print — 2025-09-19 · S · McGuire Annie · 2,283 shares
- 53 days before the 2025-02-24 print — 2025-01-02 · S · EASTHAM KARIN · 5,309 shares
- 53 days before the 2025-02-24 print — 2025-01-02 · S · EASTHAM KARIN · 4,691 shares
- 61 days before the 2025-05-07 print — 2025-03-07 · S · Leite John · 2,400 shares
- 61 days before the 2025-05-07 print — 2025-03-07 · S · Leite John · 5,011 shares
- 61 days before the 2025-11-04 print — 2025-09-04 · S · Stapley Marc · 7,667 shares
- 64 days before the 2025-05-07 print — 2025-03-04 · S · McGuire Annie · 1,142 shares
- 64 days before the 2025-05-07 print — 2025-03-04 · S · Stapley Marc · 28,189 shares
- 64 days before the 2025-05-07 print — 2025-03-04 · S · Stapley Marc · 23,414 shares
- 64 days before the 2025-05-07 print — 2025-03-04 · S · Stapley Marc · 1,094 shares
Interval to the next reported results date
For each transaction filed under a plan, the days between the transaction date and the company’s next results print. These are the dates the filings state, printed as an interval; the page draws no conclusion from them.
- 0Within 5 days of a print
- 0Within 10 days of a print
- 21Shortest interval, in days
- 0Trades with no later print on file
Adoption dates, as the filings state them
- 2024-08-13 stated in 1 filing
- 2024-08-20 stated in 1 filing
- 2024-09-04 stated in 2 filings
- 2024-09-13 stated in 2 filings
- 2024-12-06 stated in 1 filing
As the filings state it: “10b5-1 plan adopted by the reporting person on August 20, 2024”
Reported results dates on file
- 2025-02-24
- 2025-05-07
- 2025-08-06
- 2025-11-04
- 2026-01-12
- 2026-02-25
- 2026-05-05
- 2026-07-30
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- HCA Healthcare, Inc. 1
- LABCORP HOLDINGS INC. 10
- DAVITA INC. 1
- QUEST DIAGNOSTICS INC 15
- EXACT SCIENCES CORP 2
- ENSIGN GROUP, INC 13
- CareDx, Inc. 3
- CASTLE BIOSCIENCES INC 15
- Teladoc Health, Inc. 3
- SERA PROGNOSTICS, INC. 14
Order the document
Every company with plan records →
Form 4 statements and their footnotes from the SEC’s EDGAR full-text search, and this company’s results dates, industry classification and state of incorporation from the SEC submissions API. The page prints the dates the filings state and the interval between them; it draws no conclusion from them.